The Role of the Glutamatergic System in the Extinction of Conditioned Reinforcement Processes
NCT ID: NCT00926900
Last Updated: 2011-11-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE2/PHASE3
80 participants
INTERVENTIONAL
2009-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It is hypothesised that targeted treatment with D-Cycloserine prior to each extinction training session enhances the effects on cue-reactivity.
Further, a significant correlation between the reduction of cue-reactivity and both reduced craving and relapse probability is expected.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
BASIC_SCIENCE
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
D-cycloserine
D-cycloserine
50 mg at approximately 1.5 hours prior to cue-exposure training sessions
Placebo
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
D-cycloserine
50 mg at approximately 1.5 hours prior to cue-exposure training sessions
Placebo
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* controlled abstinence for a period of 5 to 21 days following admission to inpatient detoxification or day-clinic care
* women (in childbearing age): use of a highly effective method of contraception
* normal or corrected-to-normal vision
* ability to provide written informed consent
Exclusion Criteria
* positive drug screening
* current medication with anti-convulsive or psychotropic drugs
* MRI ineligibility
* sensitivity to study medication as evidenced by a history of adverse drug experience
* severe withdrawal symptoms (e.g. convulsions, delirium)
* disposition towards experiencing convulsions/ epilepsy
* history of schizophrenic disorders/ affective psychosis
* neurological diseases that might affect the dopaminergic, limbic and frontal cortices or extrapyramidal motor functioning
* major diseases (e.g. diabetes, liver cirrhosis, heart disease)
* physical illness interfering with study procedures or affecting study outcomes
* pregnancy (positive test results)/ lactation period
* suicidal tendencies/ increased risk that others might be harmed -
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
German Research Foundation
OTHER
Central Institute of Mental Health, Mannheim
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Falk Kiefer, Professor
Role: PRINCIPAL_INVESTIGATOR
Central Institute of Mental Health, Department of Addictive Behavior and Addiction Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Central Institute of Mental Health
Mannheim, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Falk Kiefer, Professor
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Strosche A, Zhang X, Kirsch M, Hermann D, Ende G, Kiefer F, Vollstadt-Klein S. Investigation of brain functional connectivity to assess cognitive control over cue-processing in Alcohol Use Disorder. Addict Biol. 2021 Jan;26(1):e12863. doi: 10.1111/adb.12863. Epub 2020 Jan 6.
Vollstadt-Klein S, Loeber S, Kirsch M, Bach P, Richter A, Buhler M, von der Goltz C, Hermann D, Mann K, Kiefer F. Effects of cue-exposure treatment on neural cue reactivity in alcohol dependence: a randomized trial. Biol Psychiatry. 2011 Jun 1;69(11):1060-6. doi: 10.1016/j.biopsych.2010.12.016. Epub 2011 Feb 3.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SFB636 D6 2006-007090-72
Identifier Type: -
Identifier Source: org_study_id